How many drugs treat Carcinoma of breast?

Drug Landscape tracks 10 marketed treatments for Carcinoma of breast (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/carcinoma-of-breast.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Carcinoma of breast — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carcinoma of breast (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Carcinoma of breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Afinitor	everolimus	Novartis	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase mTOR	2009-01-01
Ixempra Kit	IXABEPILONE	R-Pharm Us Llc	Microtubule Inhibitor	Apoptosis regulator Bcl-2	2007-01-01
Ellence	EPIRUBICIN	Pfizer	Anthracycline Topoisomerase Inhibitor	Tyrosine-protein kinase Fyn	1999-01-01
Taxotere	Docetaxel	Sanofi	Microtubule Inhibitor [EPC]	Growth hormone-releasing hormone receptor	1996-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	Alkylating agent	Tumor cell DNA	1959-01-01
Afinitor	Afinitor	Central European Society for Anticancer Drug Research		Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Carcinoma of breast
Baxter · 2 drugs in Carcinoma of breast
Chipscreen Biosciences, Ltd. · 1 drug in Carcinoma of breast
Fudan University · 1 drug in Carcinoma of breast
Hoffmann-La Roche · 1 drug in Carcinoma of breast
Johann Wolfgang Goethe University Hospital · 1 drug in Carcinoma of breast
M.D. Anderson Cancer Center · 1 drug in Carcinoma of breast
Novartis · 1 drug in Carcinoma of breast
Central European Society for Anticancer Drug Research · 1 drug in Carcinoma of breast
R-Pharm Us Llc · 1 drug in Carcinoma of breast
Sanofi · 1 drug in Carcinoma of breast
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in Carcinoma of breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Carcinoma of breast:

Cite this brief

Drug Landscape (2026). Carcinoma of breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/carcinoma-of-breast. Accessed 2026-06-10.

Carcinoma of breast full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing